Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439348 | 1.00 | CNR1 (0.44) | CNR1MMP13MMP1MMP9ROCK2 | |
| SCHEMBL23795306 | 1.00 | CNR1 (0.44) | CNR1MMP13MMP1MMP9ROCK2 | |
| SCHEMBL23810437 | 0.89 | MMP13 (0.45) | CNR1MMP13MMP1MMP9ROCK2 | |
| SCHEMBL23795420 | 0.89 | MMP13 (0.45) | CNR1MMP13MMP1MMP9ROCK2 | |
| SCHEMBL24178153 | 0.88 | MMP13 (0.41) | MMP13MMP1MMP9HTR6ADAM17 | |
| SCHEMBL23795368 | 0.88 | MMP13 (0.41) | MMP13MMP1MMP9HTR6ADAM17 | |
| SCHEMBL24177901 | 0.85 | HTR6 (0.39) | MMP13MMP1MMP9ROCK2ROCK1 | |
| SCHEMBL23795379 | 0.85 | HTR6 (0.39) | MMP13MMP1MMP9ROCK2ROCK1 | |
| SCHEMBL31399749 | 0.84 | CHRM1 (0.49) | CNR1MMP1MMP9HTR6GPR119 | |
| SCHEMBL23810413 | 0.84 | ROCK2 (0.45) | CNR1MMP13MMP1MMP9ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) | 2022-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002265-A1 | RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF | ROCK1, RHOA, ROCK2 | CNR1 3257/4885MMP13 269/4885MMP1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.